Showing results (111-120 of 119) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 119 results.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 13, 2026
Comorbidity, treatment toxicity and satisfaction with cancer care: an international cross-sectional study based on the EORTC PATSAT-C33 and OUT-PATSAT7Anne Brédart, Jean-Luc Kop, Omar Shamieh, et al.
BMC Cancer|November 27, 2025
Phase IV international prospective validation of the EORTC patient satisfaction core questionnaire (EORTC PATSAT-C33) and outpatient module (EORTC OUT-PATSAT7)Anne Brédart, Jean-Luc Kop, Omar Shamieh, et al.
JCO Clinical Cancer Informatics|April 29, 2026
Deep Learning of Histopathology Predicts Outcomes After Surgery for Pancreatic CancerAvelyn Wong, Taib A Bourega, Rémy Nicolle, et al.
JAMA Oncology|April 21, 2022
Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Systematic Review and Delphi Consensus StatementEsther N Pijnappel, J Annelie Suurmeijer, Bas Groot Koerkamp, et al.
The New England Journal of Medicine|December 22, 2018
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic CancerThierry Conroy, Pascal Hammel, Mohamed Hebbar, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2018
The EORTC CAT Core-The computer adaptive version of the EORTC QLQ-C30 questionnaireMorten Aa Petersen, Neil K Aaronson, Juan I Arraras, et al.
Breast (Edinburgh, Scotland)|February 13, 2025
An international Phase IV field study - psychometric properties of the updated module on assessing quality of life of patients with breast cancer EORTC QLQ-BR42Vesna Bjelic-Radisic, Fatima Cardoso, Joachim Weis, et al.
The Lancet. Oncology|March 7, 2018
Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable diseaseEmil Ter Veer, L Bengt van Rijssen, Marc G Besselink, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2014
Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials)Franck Bonnetain, Bert Bonsing, Thierry Conroy, et al.
Pageof 12